This article first appeared on GuruFocus .
-
Net Sales:CHF240 million in 2025, a slight decrease of 0.2% in local currencies.
-
Operating Margin:Decreased from 10.7% to 8.8%.
-
Free Cash Flow:CHF8 million, significantly below prior year.
-
Equity Ratio:Decreased from 58.2% to 54.9%.
-
Net Profit:Decreased by 27% to CHF14.9 million, representing a profit margin of 6.2%.
-
Gross Margin:Decreased from 66.2% to 65.5%.
-
Regional Sales - North America:CHF113 million, a decline of 7.5% in Swiss francs, 1.3% in local currency.
-
Regional Sales - EMEA:Increased by 1.5%.
-
Operating Cash Flow:Decreased by 51.8% to CHF13.8 million.
-
Tax Rate:19.0%, down from 22.7% in 2024.
-
Warning! GuruFocus has detected 3 Warning Signs with XSWX:CLTN.
-
Is XSWX:CLTN fairly valued? Test your thesis with our free DCF calculator.
Release Date: March 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Coltene Holding AG ( XSWX:CLTN ) maintained net sales at the previous year's level in local currencies despite market uncertainties.
-
The company saw a strong performance in the second half of 2025, with a growth of 4.7% in local currencies and an operating margin of 11%.
-
Coltene launched a new HYDRIM instrument washer in Canada, which received positive customer feedback and contributed to growth.
-
The company has invested in digital marketing and implemented a cloud-based CRM system to enhance sales and customer engagement.
-
Coltene's strategic focus on digital marketing and operational excellence, particularly in North America, is expected to drive future growth.
Negative Points
-
Operating margin decreased from 10.7% to 8.8%, and free cash flow was significantly below the prior year at CHF8 million.
-
The equity ratio decreased from 58.2% to 54.9%, impacted by foreign currency differences.
-
Net sales decreased by 4.0% in the reporting currency Swiss franc, affected by the weakening of the US and Canadian dollar and the euro.
-
The company faced challenges in the equipment business due to economic uncertainty, particularly in North America.
-
Coltene experienced a destocking of dealers in the area of impression material and wound treatment, impacting sales.
Q & A Highlights
Q: Could you elaborate on Coltene's exposure to Dental Service Organizations (DSOs) in North America and Europe? A: Our major focus is on North America, where the largest percentage of DSOs is located. We have a dedicated organization focusing on DSOs, but our market share with DSOs is still lower compared to individual dentists. In Europe, we have established an organization to focus on DSOs, particularly in the UK and Nordics, where we were previously underrepresented. Our exposure to DSOs varies by country, ranging from 0% to 15% of our business.
Q: How is the VBP program in China affecting Coltene's business? A: The VBP program in China has impacted one of our consumable products in the wound treatment segment. Dealers have started destocking due to the government tender, which affects pricing. However, only one product is currently affected by this program, and the rest of our portfolio remains unaffected.
Q: What impact have tariffs in North America had on Coltene, and how are you addressing them? A: We started paying US tariffs with the Liberation Day, initially at 10%, which later increased to 15%. We implemented countermeasures, including price increases across our product portfolio, which were absorbed by the market. These measures took effect with a time delay, impacting the first half of the year negatively, but we saw positive effects in the second half.
Q: What are the expectations for Coltene's EBIT margin improvement from 2026 to 2028? A: The growth in EBIT margin will be driven by increased production without additional investment, cost savings through global purchasing, price increases, and efficiency gains in operations. We also plan to leverage AI to reduce structural costs. The base of 2025 was lower due to tariffs, which we expect not to see in 2026, aiding margin improvement.
Q: How did Coltene's performance differ between the first and second halves of 2025? A: The first half of 2025 saw a decline due to dealer contract transitions, strategic execution changes, and delayed equipment purchases in North America. In the second half, improved dealer management, strategic execution, and a release of delayed equipment investments led to a positive performance.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
